The focus of the round will be “Aufklärung zur allogenen SZT – was Ärzte sagen und Patienten hören” („Informed consent on allogeneic SCT – what doctors say and patients hear“).
Prof. Dr. Anne Herrmann-Johns, Prof. Dr. Daniel Wolff and Mrs Ingrid Schön will be attending the round.
For more information, please read the attached event brochure.
Within the Collaborative Research Centre/Transregio (CRC/TRR) 221 innovative immune modulation strategies will be investigated to separate GvHD from GvL effects in order to enhance the safety and efficacy of allo-HSCT in the future.